Main

Fields of interest:

• Use of HmgGCoA reductase inhibitors (statins) in the management and prevention of coronary artery disease
• Use of novel anti-platelet agents in acute coronary syndromes

Recent publications:

M. O'Donoghue, D.A. Morrow, M.S. Sabatine, S.A. Murphy, C.H. McCabe, C.P. Cannon, E. Braunwald:
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Circulation, Vol. 113, 2006, pp. 1745-1752.

E.M. Antman, D.A. Morrow, C.H. McCabe, S.A. Murphy, M. Ruda, Z. Sadowski, A. Budaj, J.L. Lopez-Sendon, S. Guneri, F. Jiang, H.D. White, K.A.A. Fox, E. Braunwald for the ExTRACT-TIMI 25 Investigators:
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
N. Eng. J. Med., Vol. 354, (2006), pp. 1477-1488.

B.M. Scirica, D.A. Morrow, C.P. Cannon, K.K. Ray, M.S. Sabatine, P. Jarolim, A. Shui, C.H. McCabe, E. Braunwald for the PROVE IT-TIMI 22 investigators:
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT -TIMI 22 study.
J. Am. Coll. Cardiol., Vol. 47, (2006), pp. 2326-2331.

S.D. Solomon, M.M. Rice, K. Jablonski, P. Jose, M. Domanski, M. Sabatine, B.J. Gersh, J. Rouleau, M.A. Pfeffer, E. Braunwald for the PEACE Investigators: Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation, Vol. 114, (2006), pp. 26-31.

C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, E. Braunwald: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol., Vol. 48, (2006), pp. 438-445.

S. Ahmed, C.P. Cannon, S.A. Murphy, E. Braunwald: Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT -TIMI 22 trial. Eur. Heart J., Vol. 27, (2006), pp. 2323-2329.